42 results about "Interferon tau" patented technology

A method of monitoring treatment of HCV by oral administration of ovine IFN-τ is disclosed. The method includes measuring the blood levels of 2′,5′-oligoadenylate synthetase prior to and after such oral administration, and if necessary, adjusting the dose of IFN-τ until a measurable increase in blood 2′,5′-oligoadenylate synthetase level, relative to the level observed prior to administration, is observed. Also disclosed are oral-delivery compositions for use in treating HCV in an HCV-infected patient comprising ovine IFN-τ, in a dosage effective to stimulate bloodstream levels of 2′,5′-oligoadenylate synthetase.

The present invention includes interferon-tau (IFNτ) pharmaceutical compositions useful for oral administration to treat cancers, autoimmune disorders (particularly multiple sclerosis), cell proliferative disorders and viral disease.

Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described for use in combination therapies with antiviral and / or antitumor agents. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in the N-terminal region, comprised of between about residues 1-27, inclusive, by one or more substitutions selected based on the amino acid residue at the corresponding position of a mature interferon-tau (IFNτ) protein. Methods of combination therapy are also described.

The invention discloses a fusion protein consisting of sheep interleukin 2, sheep interferon gamma and sheep interferon tau and a preparation method thereof. The fusion protein is formed by connectingthe sheep interleukin 2, sheep interferon gamma and sheep interferon tau through a flexible linker, and a recombinant sheep long-acting interferon can be obtained through freeze drying after the fusion protein is compounded with a freeze-drying protective additive. The recombinant sheep long-acting interferon can obviously improve the half-life period of the sheep interferon, the half-life periodof the sheep interferon is prolonged by more than 17 times by compared with that of common sheep interferon, the fusion protein has a broad-spectrum antiviral role, and the immune response of sheep can be improved.

The invention discloses a sheep interferon Tau biological activity detection method and application thereof. The method includes following steps: adopting PCR amplification to acquire a gene segment of Mxp of sheep Mx protein; removing pCMV of pEGFP-N1 carrier plasmid; using the gene segment of Mxp of the sheep Mx protein obtained through PCR amplification to replace pCMV in original pEGFP-N1 carrier plasmid through T4DNA ligase to build pEGFP-N1-Mxp plasmid; using the pEGFP-N1-Mxp plasmid to transfect cells, and screening out a stable transfection cell line through neomycin; performing cloning culture on the screened stable transfection cell line, and adding sheep interferon Tau to co-incubate with the stable transfection cell line after going through cloning culture. In this way, Mx genepromoter activity can be activated to promote expression of EGFP in cells, and intensity of fluorescence emitted by the cells after being irradiated by an excitation light source is in positive correlation with biological activity of the sheep interferon Tau, so that the biological activity of the sheep interferon Tau can be evaluated quantitatively.